Hyperfine, Inc. (HYPR) vs iBio, Inc. (IBIO)
A side-by-side comparison of Hyperfine, Inc. and iBio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HYPR
Hyperfine, Inc.
$0.87HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
IBIO
iBio, Inc.
$1.05HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — HYPR vs IBIO
growth of $100 · dividends reinvested · last 6yHYPR -91.2% (-33.3%/yr)IBIO -99.9% (-67.0%/yr)HYPR compounded faster over this window
Log scale — wide-divergence pair
HYPR IBIO
HYPR vs IBIO: by the numbers
- •HYPR is the larger company ($73M vs $68M market cap).
- •Both run net losses; HYPR's is the smaller (-210.75% vs -33044.00% net margin).
- •HYPR grew revenue faster over the past five years (77.73% vs -46.91% CAGR).
Metrics side by side
Valuation
| Metric | HYPR | IBIO |
|---|---|---|
| P/S ratio | 4.43 | 675.23 |
| P/B ratio | 1.99 | 0.79 |
Profitability
| Metric | HYPR | IBIO |
|---|---|---|
| Gross margin | 51.41% | 100.00% |
| Operating margin | -273.43% | -35141.00% |
| Net margin | -210.75% | -33044.00% |
| ROE | -94.81% | -38.55% |
| ROIC | -62.98% | -40.22% |
Growth (annualized)
| Metric | HYPR | IBIO |
|---|---|---|
| Revenue CAGR (5Y) | 77.73% | -46.91% |
| Total return CAGR (5Y) | -38.34% | -70.43% |
Frequently asked
- Which has grown faster, HYPR or IBIO?
- Over the past five years, HYPR grew revenue faster — HYPR at a 77.73% CAGR versus IBIO at -46.91%.
- How have HYPR and IBIO total returns compared?
- Over the past 5 years, HYPR delivered -38.34% and IBIO delivered -70.43% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Hyperfine ROEiBio ROEHyperfine operating marginiBio operating marginHyperfine revenue growthiBio revenue growthHyperfine free cash flowiBio free cash flow
Hyperfine & iBio appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.